BiotechTube
Oncolines

Oncolines

Utrecht, Netherlands· Est.
oncolines.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Oncolines operates as a specialized contract research organization (CRO) focused on precision oncology, offering a comprehensive suite of in vitro and bioinformatic services to support oncology drug discovery and development. The company leverages its proprietary panel of cancer cell lines, proliferation assays, combination synergy studies, and advanced data analysis tools to help clients identify drug mechanisms, validate targets, understand resistance, and stratify patient populations. Its service-based model positions it as a critical partner for biopharma companies aiming to de-risk and accelerate their oncology pipelines.

Oncology

Technology Platform

Integrated precision oncology service platform combining a proprietary panel of cancer cell lines, proliferation assays, mechanistic cell biology tools (ResidenceTimer™, SPR), combination synergy studies (SynergyFinder™), and proprietary bioinformatics software (GeneNominator™, ProteomicsProfiler™) for target validation, MoA elucidation, biomarker discovery, and resistance analysis.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The growing complexity of oncology drug development, especially in combination therapies, novel modalities (e.g., PROTACs), and resistance management, creates sustained demand for deep mechanistic profiling services.
Expansion of its reference library and bioinformatics tools allows it to offer more comprehensive benchmarking and insight, potentially attracting larger pharma partnerships.

Risk Factors

Revenue is tied to client R&D budgets, making it susceptible to biopharma sector downturns.
Faces competition from both large global CROs and niche oncology labs.
Its service-based model has limited upside compared to therapeutic asset ownership and is dependent on retaining key scientific talent and continuous platform innovation.

Competitive Landscape

Oncolines competes in the preclinical oncology CRO segment against large, diversified players like Labcorp and Charles River, as well as specialized oncology-focused service providers. Its key differentiator is the deep integration of bespoke bioinformatics (GeneNominator™, ProteomicsProfiler™) with wet-lab biology, offering not just data but mechanistic insight, which appeals to clients needing de-risking for precision medicine approaches.

More companies in Oncology (General) →More companies in Netherlands →